Goodsurance
ES

Drug prices & Part D

Federal Court Rules Drug Companies Cannot Override 340B Discount Rules Without Government Approval

A unanimous three-judge panel told major pharmaceutical manufacturers that only the federal government can decide how hospitals and clinics receive their mandated drug discounts.

By the Goodsurance editorial teamJuly 22, 2026

The U.S. Court of Appeals for the District of Columbia Circuit ruled on July 21, 2026, that drug manufacturers may not unilaterally replace the traditional upfront-discount structure of the 340B Drug Pricing Program with a post-purchase rebate model. The case was brought by four drug companies, Novartis, Johnson and Johnson Health Care Systems, Bristol Myers Squibb, and Eli Lilly, each arguing it had the legal right to redesign how eligible hospitals and clinics receive their 340B savings.

The three-judge panel disagreed. Writing for the court, Judge Bradley Garcia found that while the statute permits both upfront discounts and rebates, control over which approach is used belongs to the HHS Secretary, not manufacturers. "The statute places the Secretary, not the manufacturers, in the driver's seat," Garcia wrote. The ruling affirms a 2025 district court decision and does not prevent HHS from approving a rebate model in the future.

The 340B program requires drug companies to sell medications at steep discounts to hospitals, community health centers, and other covered entities that serve large numbers of low-income or uninsured patients, many of whom are also Medicare beneficiaries. The savings help those facilities fund services across their patient populations.

Drug companies cannot rewrite 340B discount rules on their own. A federal appeals court put that authority firmly with the government.

In plain words

A federal appeals court said four large drug companies cannot change the rules of a drug-discount program on their own. The program is called 340B. It lets certain hospitals and clinics buy medicines at a lower price. The companies wanted to switch from giving discounts upfront to paying rebates later. The court said only the government can make that call. Many hospitals in this program treat Medicare patients, and the savings help fund their care.

Source: American Hospital Association
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026

Drug prices & Part D

A Customs Rule That Would Have Complicated Drug Orders From Canada Is Delayed Three Months

A new paperwork and bonding requirement for international mail containing medications was set to take effect today but was pushed back to January 20, 2027, preserving a cost-saving pathway that many Medicare beneficiaries and other older adults have come to rely on.

October 22, 2026

Drug prices & Part D

CMS Proposes Eliminating the 1-Dollar Generic Drug Copay for the Lowest-Income Medicare Dual Enrollees

A proposed rule published today in the Federal Register would bring the Part D generic drug copayment to zero for full-benefit dual eligible individuals at or below the Federal Poverty Level, starting in 2028.

October 20, 2026